• Louise Leong

    Posted in category Opinion by Louise Leong on 21/10/2013

    An experimental medicine model to support a stratified medicine approach

In the second of a series of blogs in the run-up to the ‘360° of Health Data’ conference, the ABPI’s Head of Research and Development, Louise Leong, talks about stratified medicine – a topic expected to be a big talking point amongst delegates.

 

​I have long been a champion of stratified medicine as a science and data-driven approach to developing targeted medicines. I believe we are entering an exciting period for stratified medicines. It is not just a scenario for the future, it’s happening right now - many of our member companies have produced and are developing stratified medicines. Just a few examples include maraviroc for HIV, panitimumab for colorectal cancer and gefitinib and crizotinib for lung cancer.

I was really pleased to be part of the development of the ABPI White Paper, ‘The stratification of disease for personalised medicines: Research driven recommendations and the rationale for a UK Stakeholder Alliance', which set out the vision for making the UK a globally attractive place for companies to research and develop personalised medicine. Subsequently, through the Life Science Strategy, UK government has added to the wealth of resource for translational and stratified medicine and the 100,000 Genomes project is another exciting initiative recently launched which we are supportive of - I look forward to the results of its pilot next year.

Building on the increased opportunities and eagerness to work in partnership across sectors, the ABPI recently launched a new publication, ‘An experimental medicine model to support a stratified medicine approach’  that sets out useful points to consider, with the aim of encouraging a stratified medicine approach to medicines development, and cross-sector partnership working. I am grateful to Odile Dewit, the paper’s principal author in collaboration between the ABPI Experimental Medicine Expert Network and the ABPI Stratified Medicine Working Group. 

Of course, other planks in the environmental scaffold also need to be strengthened. The ability to link medical and biological information is essential for stratified medicine to be a true accelerator of medicines development. We will be looking at this in more detail at the conference in November, exploring how the UK - with deep longitudinal records and a growing analytics capability - can lead the stratified medicines agenda and transform how patient care is managed.

Hear more about big data’s role in stratified medicine, now and in the future, at the ABPI and National Institute for Health Research (NIHR) conference ‘360O of Health Data: Harnessing Big Data for Better Health’ on 21 November 2013.

Programme and registration details at www.abpievents.org.uk

Username: R&DConference, Password: November2013

Dr Louise Leong
ABPI Head of Research and Development.

 
Print this page icon Print this page
 
Please choose the subject of your enquiry from the list below:
 
Code to enter for submitting the form
Enter the above code here:
Can't read? Try different words.